GlaxoSmithKline is pushing for lower penalties in a case brought by the Australian Competition and Consumer Commission alleging the pharma giant breached the Australian Consumer Law in the marketing for its Voltaren Osteo Gel and Voltaren Emulgel pain relief products.
